Stock Pulse
Envista Holdings (NVST) showcased innovations in dental imaging technology at IDS 2025 [6], but also faced a recall of its intraocular lenses, potentially impacting revenue by $70-$90 million [7]. Q4 2024 revenues slightly beat expectations, but missed EPS guidance leading to a stock decline [4]. While a DCF model suggests the stock is undervalued [1], Zacks recommends a hold rating due to macroeconomic headwinds [2]. Longer-term stock performance remains negative, with concerns about profitability and growth [5]. The company's chief accounting officer increased his net ownership through stock options and RSU vesting [9]. Envista's growth in specialty products, particularly Spark technology, and strategic acquisitions are positive developments, but the IOL recall and EPS miss present significant challenges [2].